# Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

> **NCT03979131** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vall d'Hebron Institute of Oncology** · enrollment: 40 (actual)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Stomach Neoplasms

## Interventions

- **COMBINATION_PRODUCT:** Avelumab addition to perioperative chemotherapy in GC and GEJC

## Key facts

- **NCT ID:** NCT03979131
- **Lead sponsor:** Vall d'Hebron Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-22
- **Primary completion:** 2023-03-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03979131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03979131, "Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03979131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*